Basket trial
Test one targeted treatment across disease groups with a shared marker, while keeping each group's results visible.
Why this level?
A single case series has post-test or pre-test/post-test outcomes, without a comparison group. NHMRC 2009 sourceThe single-arm version taught here has no concurrent control and matches an NHMRC intervention case series, level IV. A randomized basket would be classified by that allocation instead.
Fit
When to use it, and when not to
Use it when
- You have a treatment aimed at a marker found across tumor types.
- You can recruit and report each disease cohort with a clear marker assay.
Not when
- You need a definitive comparison against usual care. Use randomization within eligible cohorts. Read: Randomized controlled trial
- You need several marker-matched treatments within one tumor type. Use an umbrella trial.
Before you start
What you need
- The shared marker and assayDefine positivity, assay performance and specimen handling.
- The disease groupsSet eligibility and recruitment targets separately for each group.
- The response definition and timingoutcomeTypeUse common assessment rules and record duration and harms.
- Whether cohorts share statistical informationSpecify pooling or borrowing rules, stopping rules and sensitivity to different treatment effects.
- Assumptions and methods for missing dataCompare missing completely at random, missing at random and missing not at random. Describe which data are absent.
- The target is relevant in each tumor context.How to check: Assess biology and prior evidence by disease group.
- Response is measured consistently.How to check: Use prespecified assessment times and independent review where feasible.
- Any borrowing allows plausible differences between cohorts.How to check: Simulate scenarios with benefit in some groups and no benefit in others.
- Missing at random may be plausible after recorded predictors are included.How to check: Consider multiple imputation for missing covariates under missing at random. Multiple imputation is not inherently better.
- Missing not at random remains possible.How to check: Use a delta or tipping-point sensitivity analysis for missing not at random.
Plain language
How it works
Enroll patients with different tumor types that share a defined molecular feature. Give the targeted treatment under one protocol and assess each disease cohort. The version taught here is single-arm.
Some basket trials instead randomize within cohorts. A marker can act differently across tissue types, so a pooled response rate may mislead. If the design borrows information across cohorts, state and test the assumptions that make sharing credible. CONSORT applies to randomized variants. For a single-arm basket, report cohort flow, response rules and uncertainty without implying randomization.
Worked example
A worked example
- Setting
- Two tumor cohorts share a marker and receive the same drug.
- Question
- Is there a signal of activity in each group?
- Approach
- Report each cohort separately before considering any pooling.
- Result
- Cohort A has 8 responses among 20 patients, or 40 in 100. Cohort B has 2 among 20, or 10 in 100.
- What it means
- Together that is 10 of 40, or 25 in 100. The pooled rate hides a marked difference and proves no comparative treatment benefit.
In practice
Recent studies PubMed search · not vetted
Watch out
Common mistakes
The one to remember
A shared marker does not guarantee a shared response across tumor types. Uncontrolled response rates describe activity; they do not establish benefit against usual care.
- Assuming the same marker guarantees the same effect.Instead: Keep cohort results visible. Let differences in tumor biology inform the borrowing plan.
- Using an uncontrolled response rate as a causal treatment effect.Instead: Treat it as activity evidence. Comparative benefit needs a suitable control design.
- Dropping patients whose exposure or predictors could not be measured.Instead: This can cause selection bias. Retain people with multiple imputation when missing at random is plausible; assess departures.
Inside Mallard
How Mallard uses this
Plans do not link to this design yet. Mallard has no dedicated sizing form for basket trial.
design.basket_trial, the id a plan cue records.Related Learn pages
Related designs and methods
Evidence
Sources & further reading
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations (opens in a new tab) · N Engl J Med · doi 10.1056/NEJMoa1502309
- Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children (opens in a new tab) · N Engl J Med · doi 10.1056/NEJMoa1714448
- CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials (opens in a new tab) · BMJ · doi 10.1136/bmj.c332
- Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls (opens in a new tab) · BMJ · doi 10.1136/bmj.b2393